Abstract: Background and purpose: The pathological type of lymphoma associated with autoimmune hemolytic anemia (AIHA) is more common in indolent B lymphoma than in diffuse large B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL). This study aimed to explore the clinical features of PTCL with AIHA so as to improve the learning of this disease. Methods: Data of 7 patients with PTCL complicated by AIHA treated at the First Affiliated Hospital of Wannan Medical College from Feb. 2012 to Nov. 2018 were reviewed retrospectively. The clinical and laboratory features, treatment and follow-up results were analyzed. Results：Seven cases of PTCL patients complicated by AIHA were collected, with 5 male patients and 2 female patients, aged from 51 to 89, with a median age of 66 years. The median level of hemoglobin (Hb) was 62 (32-91) g/L, and the median ratio of reticulocytes was 4.4% (1.6%-16.0%). Of the 7 patients, 6 presented with stage Ⅲ and 1 with stage Ⅳ PTCL. The International Prognostic Index (IPI) was 2 for 2 patients, was 3 for 3 patients, was 4 for 1 patient, and was 5 for 1 patient. Four patients received prednisone during chemotherapy, 2 patients received chemotherapy only, and 1 patient received prednisone only. Among the 7 patients, 3 died. The median overall survival (OS) was 57 months. Conclusion: AIHA is a rather unusual presentation in patients with PTCL. Prognosis depends largely on the response status of PTCL. The treatment schedule is quite varied with no consensus on first-line therapy regimen. More efforts are still needed to treat this rare disease.

Key words: Autoimmune hemolytic anemia, T-cell lymphoma, Glucocorticoid, Chemotherapy